Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cardioembolic stroke: classification of causes and prevention strategies

https://doi.org/10.14412/2074-2711-2021-6-4-13

Full Text:

Abstract

This literature review covers the diversity of cardioembolic stroke (CES), the heterogeneity of the embolism sources and the morphological characteristics of the embolic substrate. It is emphasized that the determination of the individual tactics of secondary prevention is based on the verification of specific cardiac causes of stroke, for convenience, stratified as pathology of chambers, heart valves and variants of paradoxical embolism (PE). It has been shown that the leading pathology of the heart chambers associated with CES is nonvalvular atrial fibrillation and left ventricular thrombosis, and the main basis for the prevention of stroke in this pathology is oral anticoagulant therapy with direct oral anticoagulants or vitamin K antagonists (warfarin). The main types of heart valve pathology are prosthetic valves and rheumatic mitral stenosis. In this case, oral anticoagulant therapy also serves as the basis for secondary prevention. In the absence of the need to prescribe anticoagulants (mainly in the pathology of natural heart valves) acetylsalicylic acid is the drug of choice. In infective endocarditis (IE), the basic prevention strategies are antibiotic therapy and surgery. Surgical tactics also remain the main one for the prevention of CES in tumors of the left heart. Transcatheter closure of the patent foramen ovale and occlusion of the left atrial appendage are being introduced into the daily practice of interventional medicine in order to prevent ischemic stroke. A balanced individual approach to the patient, a targeted cardiological examination, a comprehensive analysis of clinical and instrumental data and the reasonable use of funds that have proven their effectiveness and safety in the main strategies for stroke prevention, are essential in effective prevention of CES.

About the Authors

A. V. Fonyakin
Research Center of Neurology
Russian Federation

Laboratory of Cardioneurology, Second Neurological Department

80, Volokolamskoe Shosse, Moscow 125367, Russia 

 



L. A. Geraskina
Research Center of Neurology
Russian Federation

Laboratory of Cardioneurology, Second Neurological Department

80, Volokolamskoe Shosse, Moscow 125367, Russia 

 



References

1. orlow ChP, Dennis MS, van Gein J, et al. Insul't. Prakticheskoye rukovodstvo dlya vedeniya bol'nykh [Stroke. A practical guide for the management of patients]. St. Petersburg: Politekhnika; 1998 (In Russ.).

2. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986 Jan;43(1):71-84.

3. Kamel H, Healey JS. Cardioembolic Stroke. Circ Res. 2017 Feb 3;120(3):514-26. doi: 10.1161/CIRCRESAHA.116.308407

4. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol. 1989 Jul;46(7):727-43.

5. Urbinelli R, Bolard P, Lemesle M, et al. Stroke patterns in cardio-embolic infarction in a population-based study. Neurol Res. 2001 Jun;23(4):309-14.doi: 10.1179/016164101101198668.

6. Suslina ZA, Fonyakin AV, Kuznetsov AL. Cardioembolic stroke: sources of embolism and ways of prevention. Atmosfera. Kardiologiya. 2004;(2):13-6 (In Russ.).

7. Hanna JP, Furlan AJ. Cardiac disease and embolic sources. In: Caplan LR, editor. Brain Ischemia: Basic Concept and Clinical Relevance. London; 1995. P. 299-315.

8. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612

9. Roberts JK, Omarali I, Di Tullio MR, et al. Valvular strands and cerebral ischemia. Effect of demographics and strand characteristics. Stroke. 1997 Nov;28(11):2185-8. doi: 10.1161/01.str.28.11.2185

10. Shiota T. Role of modern 3D echocardiography in valvular heart disease. Korean J Intern Med. 2014 Nov;29(6):685-702. doi: 10.3904/kjim.2014.29.6.685

11. Hanna JP, Sun JP, Furlan AJ, et al. Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke. 1994 Apr; 25(4):782-6. doi: 10.1161/01.str.25.4.782

12. Herrmann HC, Silvestry FE, Glaser R, et al. Percutaneous patent foramen ovale and atrial septal defect closure in adults: results and device comparison in 100 consecutive implants at a single center. Catheter Cardiovasc Interv. 2005 Feb;64(2):197-203. doi: 10.1002/ccd.20260

13. Bartz PJ, Cetta F, Cabalka AK, et al. Paradoxical emboli in children and young adults: role of atrial septal defect and patent foramen ovale device closure. Mayo Clin Proc. 2006 May; 81(5):615-8. doi: 10.4065/81.5.615

14. Soliman OI, Geleijnse ML, Meijboom FJ, et al. The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr. 2007 Jun;8(3): S2-12. doi: 10.1016/j.euje.2007.03.006

15. Jungbluth A, Erbel R, Darius H, et al. Paradoxical coronary embolism: case report and review of the literature. Am Heart J. 1988 Sep; 116(3):879-85. doi: 10.1016/0002-8703(88)90356-0

16. Onishchenko EF. Otkrytoye oval'noye okno i insul't v klinicheskoy praktike [Patent fofamen ovale and stroke in clinical practice]. St. Petersburg: ELBI-SPB; 2005 (In Russ.).

17. Gonzalez JB, Testai FD. Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke. Neurol Clin. 2021 Feb;39(1):51-69. doi: 10.1016/j.ncl.2020.09.013

18. Kuznetsov AL, Fonyakin AV, Suslina ZA. Microcerebral embolism and focal brain damage in cardioembolic stroke. Nevrologicheskiy zhurnal. 2002;(3):10-2 (In Russ.).

19. Hwang J, Choe YH. Cardiovascular sources of systemic embolism: detection and characterization using multidetector CT and MR imaging. Int J Cardiovasc Imaging. 2011 Jun;27(5):727-44. doi: 10.1007/s10554-011-9878-2

20. Fonyakin AV, Geraskina LA, Suslina ZA. The ratio of the size of the cerebral ischemic focus and the site of formation of the embologic substrate in cardioembolic stroke. Nevrologicheskiy zhurnal. 2003;8(1):10-2 (In Russ.).

21. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-21. doi: 10.1177/1747493019897870

22. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375

23. Mügge A, Kühn H, Nikutta P, et al. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol. 1994 Mar 1;23(3):599-607. doi: 10.1016/0735-1097(94)90743-9

24. Chen L, Xu C, Chen W, Zhang C. Left atrial appendage orifice area and morphology is closely associated with flow velocity in patients with nonvalvular atrial fibrillation. BMC Cardiovasc Disord. 2021 Sep 16;21(1):442. doi: 10.1186/s12872-021-02242-9

25. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994 Mar 15;23(4):961-9. doi: 10.1016/0735-1097(94)90644-0

26. Hwang JJ, Ko FN, Li YH, et al. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation. Cardiology. 1994;85(2):69-75. doi: 10.1159/000176648

27. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995 Feb;25(2):452-9. doi: 10.1016/0735-1097(94)00396-8

28. Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med. 1995 Nov 13;155(20):2193-8.

29. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997 May;77(5):407-11. doi: 10.1136/hrt.77.5.407

30. Wysokinski WE, Melduni RM, Ammash NM, et al. Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation. CJC Open. 2020 Nov 13;3(3):318-26. doi: 10.1016/j.cjco.2020.10.018

31. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J. 1996 Apr;131(4):724-30. doi: 10.1016/s0002-8703(96)90278-1

32. Wan H, Wu S, Yang Y, et al. Plasma fibrin D-dimer and the risk of left atrial thrombus: A systematic review and meta-analysis. PLoS One. 2017 Feb 16;12(2):e0172272. doi: 10.1371/journal.pone.0172272

33. Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultralow-dose warfarin and aspirin. Circulation. 1996 Aug 1;94(3):425-31. doi: 10.1161/01.cir.94.3.425

34. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997 Jan;29(1):106-12. doi: 10.1016/s0735-1097(96)00427-5

35. Kirichuk VF, Zheleznyakova NA, Kalyuta TYu, Schwartz YuG. Changes in blood viscosity in patients with coronary heart disease and atrial fibrillation: a mechanism of pathogenesis or compensation? Vestnik aritmologii. 2004;(38):13-6 (In Russ.).

36. Mooe T, Teien D, Karp K, Eriksson P. Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. Heart. 1996 Mar;75(3):252-6. doi: 10.1136/hrt.75.3.252

37. Shevchenko YuL, Odinak MM, Kuznetsov AP, Erofeev AA. Kardiogennyy i angiogennyy tserebral'nyy embolicheskiy insul't (fiziologicheskiye mekhanizmy i klinicheskiye proyavleniya) [Cardiogenic and angiogenic cerebral embolic stroke (physiological mechanisms and clinical manifestations)]. Moscow: GEOTAR-Media; 2006 (In Russ.).

38. Haugland JM, Asinger RW, Mikell FL, et al. Embolic potential of left ventricular thrombi detected by two-dimensional echocardiography. Circulation. 1984 Oct;70(4):588-98. doi: 10.1161/01.cir.70.4.588

39. Kamran S, Akhtar N, Singh R, et al. Association of Major Adverse Cardiovascular Events in Patients With Stroke and Cardiac Wall Motion Abnormalities. J Am Heart Assoc. 2021 Jul 20;10(14):e020888. doi: 10.1161/JAHA.121.020888

40. Nixon JV. Left ventricular mural thrombus. Arch Intern Med. 1983 Aug;143(8):1567-71.

41. Ye F, Silverstein BV, Khuddus MA, et al. Giant Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke: A Case Report and Minireview. Case Rep Cardiol. 2018 Jan 14;2018:3714742. doi: 10.1155/2018/3714742

42. Mizia-Stec K, Caforio ALP, Charron P, et al. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Fail. 2020 Sep 17;7(6):3601-9. doi: 10.1002/ehf2.12854

43. Oechslin EN, Attenhofer Jost CH, Rojas JR et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000 Aug;36(2):493-500. doi: 10.1016/s0735-1097(00)00755-5

44. Stöllberger C, Blazek G, Dobias C, et al. Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction. Am J Cardiol. 2011 Oct 1;108(7):1021-3. doi: 10.1016/j.amjcard.2011.05.039. Epub 2011 Jul 23.

45. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996 Jan 1;77(1):107. doi: 10.1016/s0002-9149(97)89149-7

46. Lai MM, Li TC, Lin CL, et al. Benign neoplasm of the heart increases the risk of first ischemic stroke: a population-based cohort study. Int J Stroke. 2015 Feb;10(2):202-6. doi: 10.1111/ijs.12314

47. Gowda RM, Khan IA, Nair CK, et al. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003;146:404-10. doi: 10.1016/S0002-8703(03)00249-7

48. Valente M, Basso C, Thiene G, et al. Fibroelastic papilloma: A not-so-benign cardiac tumor. Cardiovasc Pathol. 1992 AprJun;1(2):161-6. doi: 10.1016/1054-8807(92)90020-O

49. Soloviev GM, Popov LV, Ignatov YuV. Kardiokhirurgiya v ekhokardiograficheskom issledovanii [Cardiac surgery in echocardiographic research]. Moscow: Meditsina; 1990 (In Russ.).

50. Greve AM, Dalsgaard M, Bang CN, et al. Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Stroke. 2014 Jul;45(7):1939-46. doi: 10.1161/STROKEAHA.114.005296

51. Oppenheimer SM, Lima J. Neurology and the heart. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):289-97. doi: 10.1136/jnnp.64.3.289

52. Easton JD, Sherman DG. Management of cerebral embolism of cardiac origin. Stroke. 1980 Sep-Oct;11(5):433-42. doi: 10.1161/01.str.11.5.433

53. Shevchenko YuL, Mikhailenko AA, Kuznetsov AN, Erofeev AA. Kardiokhirurgicheskaya agressiya i golovnoy mozg [Cardiac aggression and the brain]. St. Petersburg: Nauka; 1997 (In Russ.).

54. Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience with Low-Intensity Anticoagulation Study. Chest. 2005 Jan;127(1):53-9. doi: 10.1378/chest.127.1.53

55. Kim AS. Evaluation and prevention of cardioembolic stroke. Continuum (Minneap Minn). 2014 Apr;20(2 Cerebrovascular Disease):309-22. doi: 10.1212/01.CON.0000446103.82420.2d

56. Shevchenko YuL, Odinak MM, Mikhailenko AA, Kuznetsov AP. Kardioembolicheskiy insul't [Cardioembolic stroke]. St. Petersburg: VMedA; 1997 (In Russ.).

57. Habib G, Lancellotti P, Antunes MJ, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-128. doi: 10.1093/eurheartj/ehv319

58. Del Giudice C, Vaia E, Liccardo D, et al. Infective Endocarditis: A Focus on Oral Microbiota. Microorganisms. 2021 Jun 4;9(6):1218. doi: 10.3390/microorganisms9061218

59. Moreillon P, Que YA, Bayer AS. Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am. 2002 Jun;16(2):297-318. doi: 10.1016/s0891-5520(01)00009-5

60. Homma S, Messe SR, Rundek T, et al. Patent foramen ovale. Nat Rev Dis Primers. 2016 Jan 21;2:15086. doi: 10.1038/nrdp.2015.86

61. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984 Jan;59(1):17-20. doi: 10.1016/s0025-6196(12)60336-x

62. Wahl A, Windecker S, Meier B. Patent foramen ovale: pathophysiology and therapeutic options in symptomatic patients. Minerva Cardioangiol. 2001 Dec;49(6):403-11.

63. Suslina ZA, Fonyakin AV, Chechetkin AO, et al. Comparative clinical and instrumental characteristics of patients with an patent foramen ovale with refined and cryptogenic ischemic stroke. Kardiologiya 2010;(11):50-4 (In Russ.).

64. Suslina ZA, Fonyakin AV, Geraskina LA, et al. Prakticheskaya kardionevrologiya [Practical cardioneurology]. Moscow: IMA-Press; 2010 (In Russ.).

65. Maida CD, Norrito RL, Daidone M, et al. Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches. Int J Mol Sci. 2020 Sep 4;21(18):6454. doi: 10.3390/ijms21186454

66. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999 Oct 5;131(7):492-501. doi: 10.7326/0003-4819-131-7-199910050-00003

67. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007

68. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561

69. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010 Mar;159(3):340-7.e1. doi: 10.1016/j.ahj.2009.11.025

70. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432

71. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018 Oct 9;138(15):1519-29. doi: 10.1161/CIRCULATIONAHA.118.035418

72. Breithardt G, Baumgartner H, Berkowitz SD, et al; ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014 Dec 14;35(47):3377-85. doi: 10.1093/eurheartj/ehu305

73. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807

74. Pan KL, Singer DE, Ovbiagele B, et al. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and MetaAnalysis. J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835

75. Witt BJ, Brown RD Jr, Jacobsen SJ, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005 Dec 6;143(11):785-92. doi: 10.7326/0003-4819-143-11-200512060-00006

76. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993 Oct;22(4):1004-9. doi: 10.1016/0735-1097(93)90409-t

77. Fleddermann AM, Hayes CH, Magalski A, Main ML. Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus. Am J Cardiol. 2019 Aug 1;124(3):367-72. doi: 10.1016/j.amjcard.2019.05.009. Epub 2019 May 8.

78. Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020 Jun 1;5(6):685-92. doi: 10.1001/jamacardio.2020.0652

79. Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. Cardiac Magnetic Resonance Imaging for the Diagnosis of Left Ventricular Thrombus: A Systematic Review. Can J Cardiol. 2015 Jun;31(6):785-91. doi: 10.1016/j.cjca.2015.01.011. Epub 2015 Jan 24.

80. Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the «LOWERING-IT» Trial. Am Heart J. 2010 Jul;160(1):171-8. doi: 10.1016/j.ahj.2010.05.005

81. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305

82. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-e227. doi: 10.1161/CIR.0000000000000923. Epub 2020 Dec 17.

83. Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007 Nov;16(6):667-71.

84. Eikelboom JW, Connolly SJ, Brueckmann M, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31.

85. Goette A, Kalman JM, Aguinaga L, et al; Document Reviewers: EHRA/HRS/APHRS/ SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016 Oct;18(10):1455-90. doi: 10.1093/europace/euw161. Epub 2016 Jul 8.

86. Guichard JB, Nattel S. Atrial Cardiomyopathy: A Useful Notion in Cardiac Disease Management or a Passing Fad? J Am Coll Cardiol. 2017 Aug 8;70(6):756-65. doi: 10.1016/j.jacc.2017.06.033

87. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996 Feb;61(2):755-9. doi: 10.1016/0003-4975(95)00887-X

88. Reddy VY, Doshi SK, Kar S, et al; PREVAIL and PROTECT AF Investigators. 5-Year Outcomes after Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-75. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4.

89. Kent DM, Dahabreh IJ, Ruthazer R, et al. Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials. J Am Coll Cardiol. 2016 Mar 1;67(8):907-17. doi: 10.1016/j.jacc.2015.12.023

90. Lee PH, Song JK, Kim JS, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018 May 22;71(20):2335-42. doi: 10.1016/j.jacc.2018.02.046. Epub 2018 Mar 12.

91. Mas JL, Derumeaux G, Guillon B, et al; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-21. doi: 10.1056/NEJMoa1705915

92. Saver JL, Carroll JD, Thaler DE, et al; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-32. doi: 10.1056/NEJMoa1610057

93. S∅ndergaard L, Kasner SE, Rhodes JF, et al; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017 Sep 14;377(11):1033-42. doi: 10.1056/NEJMoa1707404

94. Turc G, Lee JY, Brochet E, et al; CLOSE and DEFENSE-PFO Trial Investigators. Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients with Patent Foramen Ovale. J Am Coll Cardiol. 2020 May 12;75(18):2312-20. doi: 10.1016/j.jacc.2020.02.068

95. Alegria S, Marques A, Cruz I, et al. Neurological Complications in Patients with Infective Endocarditis: Insights from a Tertiary Centre. Arq Bras Cardiol. 2021 Apr;116(4):682-91. doi: 10.36660/abc.20190586

96. Dickerman SA, Abrutyn E, Barsic B, et al.; ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007 Dec;154(6):1086-94. doi: 10.1016/j.ahj.2007.07.023

97. Barsic B, Dickerman S, Krajinovic V, et al; International Collaboration on Endocarditis - Prospective Cohort Study Investigators. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis. 2013 Jan;56(2):209-17. doi: 10.1093/cid/cis878. Epub 2012 Oct 16.

98. Elbardissi AW, Dearani JA, Daly RC, et al. Embolic potential of cardiac tumors and outcome after resection: a case-control study. Stroke. 2009 Jan;40(1):156-62. doi: 10.1161/STROKEAHA.108.525709. Epub 2008 Oct 23.


For citation:


Fonyakin A.V., Geraskina L.A. Cardioembolic stroke: classification of causes and prevention strategies. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):4-13. (In Russ.) https://doi.org/10.14412/2074-2711-2021-6-4-13

Views: 93


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)